Announcements Trials

Browse Landscape

Phase

Phase NA 1 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Fatigue 4 Neoplasms 3 Sleepiness 1 Prostatic Neoplasms 1 Pain 1 Multiple Myeloma 1 Disorders of Excessive Somnolence 1 Cancer Related Fatigue 1 Breast Neoplasms 1 Brain Neoplasms 1

Interventions

Radiotherapy 8 Zoledronic Acid 7 Fentanyl 7 nabiximols 6 Morphine 6 Ibandronic Acid 6 Ketamine 5 Hydromorphone 5 Analgesia 5 Acetaminophen 5 Tapentadol 4 Oxycodone 4 Acupuncture Therapy 4 alvimopan 3 Ropivacaine 3 Prednisone 3 Lidocaine 3 cabozantinib 2 Tetrodotoxin 2 Mitoxantrone 2 Gabapentin 2 Duloxetine Hydrochloride 2 Docetaxel 2 Calcium 2 6'-fluoro-4',9'-dihydro-N,N-dimethyl-4-phenylspiro(cyclohexane-1,1'(3'H)-pyrano(3,4-b)indol)-4-amine 2 strontium chloride 1 resiniferatoxin 1 oxycodone-acetaminophen 1 oxycodone naloxone combination 1 ixabepilone 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Pain × Modafinil × Clear all

NCT00267332 2018-05-07

Modafinil in Opioid Induced Sedation

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 3 Terminated

Neoplasms, Pain

Data powered by HemOnc (CC BY 4.0) Colophon ⚡